Clinical Trial Update: A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma [Phase 1]

View source ↗

Summary

It notes the completion of a Phase I trial evaluating the continuous infusion immunotoxin IgG-RFB4-SMPT-dgA in refractory CD22-positive B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• IgG-RFB4-SMPT-dgA

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B Cell Lymphoma | Phase 1 | Status: COMPLETED